NTRK Fusions

ModPath Chat
07/12/2021 23 min
NTRK Fusions

Listen "NTRK Fusions"

Descargar episodio

Episode Synopsis


Identification of molecular alterations in NTRK 1-3 has become increasingly important with the emergence of histology-agnostic, US Food and Drug Administration-approved, effective inhibitors. The host discusses with Dr. Jaclyn Hechtman, director of clinical diagnostic development at Neogenomics, her practical insights on how testing for NTRK fusion can best be implemented and communicated within the multidisciplinary healthcare team.

More episodes of the podcast ModPath Chat

Invasive Lobular Carcinoma (ILC): European Lobular Breast Cancer Consortium Recommendations. Anne Vincent-Salomon and Maxim De Schepper 31/12/2024
Fumarate hydratase deficient renal cell carcinoma. Guido Martignoni and Anna Caliò 06/12/2024
Intraductal oncocytic papillary neoplasm, Claudio Luchini and Gaetano Paolini 18/11/2024
Gastrointestinal Langerhans cell histiocytosis: New insights. Shaomin Hu and Yue Xue 28/10/2024
Opening the Black Box: Spatial Transcriptomics and the Relevance of Artificial Intelligence–Detected Prognostic Regions in High-Grade Serous Carcinoma. Anna Ray Laury et al 10/10/2024
Pathologist-Driven Reflex Somatic Tumor DDR Testing in Localized Prostate Cancer. Susan Prendeville and Shamini Selvarajah 09/09/2024
Staging of Multiple NSCLC: Paradigm shift using molecular methods Natasha Rekhtman 21/08/2024
A Portrait of HER2- Low Invasive Lobular Carcinoma (ILC) of Breast. Lounes Djerroudi Anne Vincent-Salomon 02/08/2024
Special Episode - Meet the Listeners 14/06/2024
Molecular Profiling of Sinonasal Olfactory Carcinoma with Lisa Rooper, MD 31/05/2024
© 2003-2026 ZARZA | AHEAD OF OUR TIME
privacy policy
In God we trust In God we trust
PreSales Questions? Click Here
or call our toll-free line at +1-888-5002068 Miami, Florida, USA